Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused...

#APRE Aprea Therapeutics, Phase 2 Dosing Update:
www.globenewswire.com/news-release...
#combinationtherapies.

Mosaic therapeutics expands pipeline with Astex deal - PharmaTimes Cambridge firm in-licenses two oncology programmes

#oncology #precisionmedicines #cancer #cancers #MosaicTherapeutics #Astex #AstexPharmaceuticals #inlicensing #oncologyprogrammes #clinicalstageoncologyprogrammes #combinationtherapies #biomarkers #drugdiscoveryplatform #clinicaltrials
pharmatimes.com/news/mosaic-...

Vantaggi e sfide delle terapie combinate: ottimizzare l'accesso e la sostenibilità - CRESP Quali sono i vantaggi delle terapie combinate, che utilizzano due o più principi attivi con meccanismi d’azione diversi? Le evidenze cliniche mostrano sempre più l’importanza di associare diversi farm...

#ComboConnect by More Than Access & ISPOR Rome highlights the need for clearer #EMA guidance and better policies to support access to 149 approved #combinationtherapies in Italy, improving efficacy and adherence👉 www.cresp.it/vantaggi-e-s...